Brought to you by 
PathoGenesis licenses PA-1648 from Kaneka
13 Jul 1999
Executive Summary
PathoGenesis (infectious disease therapies) licensed exclusive rights in North America to Kaneka's (Japanese specialty chemical corp.) anti-infective, PA-1648 (rifalazil), a rifampin derivative, for tuberculosis and MAC infection indications.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PathoGenesis licenses PA-1648 from Kaneka
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice